Published February 1982
| Version v1
Journal article
Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer
- 1. The Johns Hopkins Oncology Center, Baltimore, MD
Description
A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated
Additional details
Publishing Information
- Journal Title
- Cancer Treat. Rep.
- Journal Volume
- 66
- Journal Issue
- 2
- Series
- Cancer Treat. Rep.
- Journal Page Range
- 289-297
- ISSN
- 0361-5960
INIS
- Country of Publication
- United States
- Country of Input or Organization
- United States
- INIS RN
- 13702566
- Subject category
- S63: RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS; S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANTIBODIES; BLOOD PLATELETS; IMMUNOTHERAPY; IODINE 131; LEUKOPENIA; LIVER; NEOPLASMS; PATIENTS; RADIATION EFFECTS; RADIOTHERAPY; TOXICITY
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY; BODY FLUIDS; DAYS LIVING RADIOISOTOPES; DIGESTIVE SYSTEM; DISEASES; GLANDS; HEMIC DISEASES; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOTOPES; MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; PATHOLOGICAL CHANGES; RADIOISOTOPES; SYMPTOMS; THERAPY